Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease

International Journal of Cardiology

Volumn 98, Issue 3, 2005, Pages 479-486

  Lemos, Pedro A ^a   De Feyter, Pim J ^a   Serruys, Patrick W ^a   Saia, Francesco ^a   Arampatzis, Chourmouzios A ^a   Disco, Clemens ^b   Mercado, Nestor ^a   Mainar, Vicente ^c   Morís, César ^d   Van Den Bos, A A ^e   Berghoefer, Gunnar ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e AMPHIA HOSPITAL   (Netherlands)

^f Vivantes Klinikum Spandau   (Germany)

Author keywords

Angioplasty; Cholesterol; Coronary disease; HMG CoA reductase inhibitors

Indexed keywords

FLUINDOSTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HAZARD ASSESSMENT; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

EID: 20844459638     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.11.031     Document Type: Article

References (28)

1. Keelan P.C., Bielak L.F., Ashai K., et al. Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation. 104:2001;412-417
2. van Domburg R.T., Foley D.P., Breeman A., van Herwerden L.A., Serruys P.W. Coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Twenty-year clinical outcome. Eur. Heart J. 23:2002;543-549
3. Hannan E.L., Racz M.J., McCallister B.D., et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 33:1999;63-72
4. Marie P.Y., Danchin N., Durand J.F., et al. Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J. Am. Coll. Cardiol. 26:1995;879-886
5. Ringqvist I., Fisher L.D., Mock M., et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J. Clin. Invest. 71:1983;1854-1866
6. Williams D.O., Holubkov R., Yeh W., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: The National Heart, Lung, and Blood Institute Registries. Circulation. 102:2000;2945-2951
7. Kornowski R., Mehran R., Satler L.F., et al. Procedural results and late clinical outcomes following multivessel coronary stenting. J. Am. Coll. Cardiol. 33:1999;420-426
8. Laskey W.K., Williams D.O., Vlachos H.A., et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am. J. Cardiol. 87(964-9):2001;A3-A4
9. Smith S.C. Jr., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J. Am. Coll. Cardiol. 37:2001;2239i-lxvi
10. SoS Investigators Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 360:2002;965-970
11. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. 344:2001;1117-1124
12. Rodriguez A., Bernardi V., Navia J., et al. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J. Am. Coll. Cardiol. 37:2001;51-58
13. Morrison D.A., Sethi G., Sacks J., et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J. Am. Coll. Cardiol. 38:2001;143-149
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339:1998;1349-1357
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
16. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22
17. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335:1996;1001-1009
18. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 287:2002;3215-3222
19. Serruys P.W., De Feyter P.J., Benghozi R., Hugenholtz P.G., Lesaffre E. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int. J. Cardiovasc. Interv. 4:2001;165-172
20. Serruys P.W., Foley D.P., Jackson G., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur. Heart J. 20:1999;58-69
21. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41
22. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128:1998;262-269
23. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K. Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340:1999;14-22
24. Davila-Roman V.G., Murphy S.F., Nickerson N.J., Kouchoukos N.T., Schechtman K.B., Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. J. Am. Coll. Cardiol. 33:1999;1308-1316
25. King S.B. III, Kosinski A.S., Guyton R.A., Lembo N.J., Weintraub W.S. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J. Am. Coll. Cardiol. 35:2000;1116-1121
26. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:2002;1773-1780
27. Degertekin M., Serruys P.W., Foley D.P., et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 106:2002;1610-1613
28. Mintz G.S., Painter J.A., Pichard A.D., et al. Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J. Am. Coll. Cardiol. 25:1995;1479-1485